Expanded Access to Investigational Medicines
Calliditas Therapeutics AB is focused on the development and commercialization of novel treatments in orphan indications, with an initial focus on renal and hepatic diseases.
At this time, Calliditas Therapeutics does not provide access to investigational products outside of clinical trials. We encourage patients to participate in clinical trials of our investigational therapies whenever possible, because clinical trials are designed, conducted, and monitored to ensure that the safety and efficacy are appropriately evaluated before they are submitted to regulatory agencies for review with the intent to make them more broadly available to patients.
You and your health care provider may learn more about our clinical trials by going to the ‘Nefecon’ section of our website here: https://www.calliditas.se/en/nefecon-2221/#clinical or visiting www.clinicaltrials.gov and searching for ‘Calliditas Therapeutics.’
If applicable, this website will be updated to include hyperlinks to any relevant expanded access information on www.clinicaltrials.gov upon activation. Calliditas Therapeutics reserves the right to revise this expanded access policy at any time.